CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS CALT 深 滬
已收盤 09-20 16:00:00 美东时间
40.0001
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 40.0001
- 總市值 10.81亿
- 52周最高 3.4777
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 -24.2723
- 委 比 0.00%
- 總股本 2701.67万
- 歷史最高 3.4777
- 量 比 0
- 振 幅 0.00%
- 歷史最低 -28.7023
- 每 手 1
- 風險率 9.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多单日暴涨130%+，肾病领域再成行业焦点
转自：新康界 4月30日，诺华公司宣布以17亿美元收购美股上市医药公司Regulus(NASDAQ:RGLS)，受此消息影响，Regulus的股价...
2025-06-23 19:50
Calliditas Therapeutics to be delisted from Nasdaq Stockholm
Calliditas Therapeutics AB (NASDAQ:CALT) said on Monday that Nasdaq Stockholm has decided the company will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, ...
2024-09-16 22:45
Calliditas Therapeutics Sets Delisting Process
Calliditas Therapeutics (CALT) has released an update. Calliditas Therapeutics,...
2024-09-04 04:51
Asahi Kasei Expands Global Pharma Presence with Calliditas Acquisition
Asahi Kasei (JP:3407) has released an update. Asahi Kasei Corporation successfu...
2024-09-03 09:27
Calliditas Therapeutics Sees Strong Sales Growth
Calliditas Therapeutics (CALT) has released an update. Calliditas Therapeutics ...
2024-08-14 04:38
Calliditas Therapeutics Q2 2024 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $52.351M Beat $42.952M Estimate
Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 26.92 percent. This is a 49.23 percent increase over losses of $(0.33) per
2024-08-13 13:40
Number of Shares and Votes in Calliditas Therapeutics
STOCKHOLM, July 31, 2024 /PRNewswire/ -- During July, the number of shares and ...
2024-07-31 20:23
Calliditas’ Setanaxib Shows Promise in PBC Trial
Calliditas Therapeutics (CALT) has released an update. Calliditas Therapeutics ...
2024-07-27 04:27
Calliditas's Kinpegyo gets EU approval, setanaxib study meets endpoint
Calliditas (NASDAQ:CALT) said its partner STADA has received full EU marketing authorization for the drug Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy, or IgAN. Kinpe...
2024-07-27 03:52
Calliditas Therapeutics Reports TRANSFORM Phase 2b Topline Data In Primary Biliary Cholangitis
alliditas Therapeutics AB (NASDAQ:CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant
2024-07-26 14:53
